Author

S. Ogden

Listed by name: these papers carry no ORCID for this author, so different people with the same name may be mixed together.

Biology Disciplines

Click to filter author papers

Cancer Biology· 5

Signature Assays, Organisms & Methods

Click to filter · or open tag

Assay:bulk RNA-seq· 4 Organism:human· 4 Approach:statistical model· 4 Research Focus:cell type annotation· 2 Research Focus:chromatin & epigenetic regulation· 2 Assay:ATAC-seq· 1 Research Focus:cancer & tumor microenvironment· 1 Research Focus:cell signaling & trafficking· 1

Frequent Co-Authors

The OCCAMS Consortium· 4 shared A. D. Sharrocks· 2 shared A. Sharrocks· 2 shared C. Francavilla· 2 shared I. Ahmed· 2 shared P. Fullwood· 2 shared A. D. Southam· 1 shared A. F. L. Hurlstone· 1 shared

Activity by Year

2020-2022 · peak 2/yr

Co-Author Collaboration Network

10 top collaborators · 25 mutual co-author links

Click any collaborator node to inspect or filter shared papers

Focal author (center)Selected co-authorORCID co-authorUnlinked name

Curved chords = mutual co-authorship

4 shared papersCancer Biology

The OCCAMS Consortium

Mutual co-authors in cluster

Author profile →

5 papers

Recent·Most cited

Oncogenic ERRB2 signals through the AP-1 transcription factor to control mesenchymal-like properties of oesophageal adenocarcinoma

S. Ogden, I. Ahmed, P. Fullwood, The OCCAMS Consortium, C. Francavilla, A. Sharrocks

This study identifies AP-1 as a key transcription factor mediating ERBB2-driven mesenchymal-like properties in oesophageal adenocarcinoma through integrated phosphoproteomics, open chromatin profiling, and transcriptome analysis.

bioRxiv · Aug 14, 2022Cancer Biology

eRNA profiling uncovers the enhancer landscape of oesophageal adenocarcinoma and reveals new deregulated pathways

I. Ahmed, S.-H. Yang, S. Ogden, Y. Li, W. Zhang, the OCCAMs consortium, A. Sharrocks

The paper identifies enhancer RNAs in oesophageal adenocarcinoma using RNA-seq and open chromatin maps, revealing new deregulated pathways and their clinical relevance.

bioRxiv · May 11, 2022Cancer Biology

Widespread reorganisation of the regulatory chromatin landscape facilitates resistance to inhibition of oncogenic ERBB2 signalling.

S. Ogden, K. Carys, J. Bruce, the OCCAMs consortium, A. D. Sharrocks

The paper shows that ERBB2 inhibition in OAC cells leads to chromatin remodelling and rewiring of gene regulatory networks, enabling resistance through metabolic shifts and transcriptional regulators.

bioRxiv · Apr 29, 2021 · PreprintCancer Biology

DGAT1 is a lipid metabolism oncoprotein that enables cancer cells to accumulate fatty acid while avoiding lipotoxicity

D. J. Wilcock, A. P. Badrock, R. Owen, M. Guerin, A. D. Southam, H. Johnston, S. Ogden, P. Fullwood, J. Watson, H. Ferguson, J. Haworth, D. A. Richardson, G. R. Lloyd, A. Jankevics, W. B. Dunn, , A. F. L. Hurlstone

This study identifies DGAT1 as an oncoprotein that enables cancer cells to accumulate fatty acids while avoiding lipotoxicity, promoting melanoma formation.

bioRxiv · Jun 23, 2020 · PreprintCancer Biology

Repurposing of KLF5 activates a cell cycle signature during the progression from a precursor state to Oesophageal Adenocarcinoma

C. Rogerson, S. Ogden, E. Britton, the OCCAMS consortium, Y. Ang, A. D. Sharrocks

The paper identifies a cell cycle gene expression signature in Oesophageal Adenocarcinoma (OAC) and shows KLF5's repurposing to regulate cell cycle genes during progression from Barrett's oesophagus to OAC.

bioRxiv · Feb 10, 2020Cancer Biology